Extracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease

Abstract

Get full access to this article

View all access options for this article.

References

Barnes

Mole

. Allogeneic lymphoid cell disease in midlethally irradiated CBA mice: The delayed harmful effects of small numbers of C3H lymphoid cells. Int J Radiat Biol Relat Stud Phys Chem Med 1969; 15:43–50.

Remberger

Ringden

Blau

. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98:1739–1745.

Beatty

Hansen

Longton

. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51:443–447.

Storek

Gooley

Siadak

. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90:4705–4709.

Gaziev

Polchi

Galimberti

. Graft-versus-host disease after bone marrow transplantation for thalassemia: An analysis of incidence and risk factors. Transplantation 1997; 63:854–860.

Lazarus

Rowe

. New and experimental therapies for treating graft-versus-host disease. Blood Rev 1995; 9:117–133.

Urbano–Ispizua

Garcia–Conde

Brunet

. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT. Haematologica 1997; 82:683–689.

Ratanatharathorn

Ayash

Lazarus

. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant 2001; 28:121–129.

Vogelsang

. How I treat chronic graft-versus-host disease. Blood 2001;97:1196–1201.

10.

Shulman

Sale

Lerner

. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91:545–570.

11.

Eppinger

Ehninger

Steinert

. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50:807–811.

12.

Aubin

Brion

Deconinck

. Phototherapy in the treatment of cutaneous graft-versus-host disease. Our preliminary experience in resistant patients. Transplantation 1995; 59:151–155.

13.

Jampel

Farmer

Vogelsang

. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991; 127:1673–1678.

14.

Vogelsang

Wolff

Altomonte

. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17:1061–1067.

15.

Basara

Gunzelmann

Willenbacher

. New immunosuppressants in BMT/GVHD. Transplant Proc 2001; 33:2220–2222.

16.

Simpson

. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res 2000; 9:317–325.

17.

Przepiorka

Kernan

Ippoliti

. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95:83–89.

18.

Vogelsang

Farmer

Hess

. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326:1055–1058.

19.

Sastry

Powles

. Thalidomide for chronic GVHD. Bone Marrow Transplant 1998; 22:933–934.

20.

Nestel

Price

Seemayer

. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175:405–413.

21.

Abhyankar

Gilliland

Ferrara

. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993; 56:1518–1523.

22.

Tanaka

Imamura

Kasai

. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 1997; 19:571–576.

23.

Sakamaki

Kuroda

. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. Blood 2001; 97:1123–1130.

24.

Fowler

Gress

. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000; 38:221–234.

25.

Ferrara

Abhyankar

Gilliland

. Cytokine storm of graft-versus-host disease: A critical effector role for interleukin-1. Transplant Proc 1993; 25:1216–1217.

26.

Ferrara

. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5:794–799.

27.

Korholz

Kunst

Hempel

. Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19:691–695.

28.

Bladon

Taylor

. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol 1999; 107:707–711.

29.

Berger

Hanlon

. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91:438–447.

30.

Rook

Freundlich

Jegasothy

. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol 1992; 128:337–346.

31.

Deeg

Graham

Gerhard-Miller

. Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. Blood 1989; 74:2592–2595.

32.

Truitt

Johnson

Hanke

. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163:5145–5156.

33.

Vink

Moodycliffe

Shreedhar

. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci USA 1997; 94:5255–5260.

34.

Owsianowski

Gollnick

Siegert

. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994; 14:845–848.

35.

Rossetti

Zulian

Dall'Amico

. Extracorporeal photochemotherapy as single therapy for expensive, cutaneous, chronic graft-versus-host disease. Transplantation 1995; 59:149–151.

36.

Rossetti

Dall'Amico

Crovetti

. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant 1996; 18Suppl 2:175–181.

37.

Dall'Amico

Rossetti

Zulian

. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97:848–854.

38.

Child

Ratnavel

Watkins

. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999; 23:881–887.

39.

Greinix

Volc–Platzer

Rabitsch

. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92:3098–3104.

40.

Greinix

Volc–Platzer

Kalhs

. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study. Blood 2000; 96:2426–2431.

41.

Alcindor

Gorgun

Miller

. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001; 98:1622–1625.

42.

Gorgun

Miller

Foss

. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100:941–947.

43.

Shlomchik

Couzens

Tang

. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412–415.

44.

Chan

Gorgun

Miller

. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9:170–176.